The first-generation EGFR TKIs, gefitinib and erlotinib, designed to reversibly compete for the adenosine triphosphate binding sites and, thus, block EGFR-induced downstream signaling activation in the lung adenocarcinoma treatment (38, 45). Here, EGFR is linked to lung adenocarcinoma.